About: Nonsurgical Management of Resectable Oral Cavity Cancer in the Wake of COVID-19: A Rapid Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nonsurgical Management of Resectable Oral Cavity Cancer in the Wake of COVID-19: A Rapid Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Nonsurgical Management of Resectable Oral Cavity Cancer in the Wake of COVID-19: A Rapid Review and Meta-Analysis
Creator	Chan, K Chan, Kelvin De Almeida, John Eskander, Antoine Forner, David Noel, W Wu, Vincent Husain, Zain Noel, Christopher Parmar, Ambica De Almeida, J Husain, Z Parmar, A Wu, V
source	Elsevier; Medline; PMC
abstract	OBJECTIVE: Surgery is the preferred treatment modality for oral squamous cell carcinoma (OSCC). However, due to limited resources, re-assessment of treatment paradigms in the wake of the Coronavirus Disease 2019 (COVID-19) pandemic is urgently required. In this rapid review, we described contemporary oncological outcomes for OSCC using non-surgical modalities. METHODS: A systematic literature search was conducted for articles published between January 1, 2010 and April 1, 2020 on MEDLINE and Cochrane CENTRAL. Studies were included if they contained patients with OSCC treated with either neoadjuvant, induction, or definitive radiotherapy, chemotherapy, immunotherapy, or combination thereof, and an outcome of overall survival. RESULTS: In total, 36 articles were identified. Definitive radiotherapy or chemoradiotherapy were the focus of 18 articles and neoadjuvant chemotherapy or chemoradiotherapy were the focus of the other 18 articles. In early stage OSCC, definitive radiotherapy, with or without concurrent chemotherapy, was associated with a significantly increased hazard of death compared to definitive surgery (HR: 2.39, 95% CI: 1.56 - 3.67, I(2): 63%). The hazard of death was non-significantly increased with definitive chemoradiotherapy in studies excluding early disease (HR: 1.98, 95% CI: 0.85 - 4.64, I(2): 84%). Two recent randomized control trials have been conducted, demonstrating no survival advantage to neoadjuvant chemotherapy. CONCLUSION: This review suggests that primary radiotherapy and chemoradiotherapy are inferior to surgical management for OSCC. Strategies for surgical delay warranting consideration are sparse, but may include several neoadjuvant regimens, recognizing these regimens may not offer a survival benefit over definitive surgery alone.
has issue date	2020-06-10(xsd:dateTime)
bibo:doi	10.1016/j.oraloncology.2020.104849
bibo:pmid	32599499
has license	no-cc
sha1sum (hex)	dabf783ac26886705f599bd27a711e9450f7ea9d
schema:url	https://doi.org/10.1016/j.oraloncology.2020.104849
resource representing a document's title	Nonsurgical Management of Resectable Oral Cavity Cancer in the Wake of COVID-19: A Rapid Review and Meta-Analysis
has PubMed Central identifier	PMC7284253
has PubMed identifier	32599499
schema:publication	Oral Oncol
resource representing a document's body	covid:dabf783ac26886705f599bd27a711e9450f7ea9d#body_text
is schema:about of	named entity 'treatment modality' named entity 'modalities' named entity 'Cancer' covid:arg/dabf783ac26886705f599bd27a711e9450f7ea9d named entity 'oral squamous cell carcinoma' named entity 'COVID-19' named entity 'Surgery' named entity 'Management' named entity 'Coronavirus Disease 2019' named entity 'Meta-Analysis' named entity 'Coronavirus Disease 2019' named entity 'self-isolation' named entity 'OSCC' named entity 'COVID-19' named entity 'immunosuppressive' named entity 'oncologists' named entity 'Febrile neutropenia' named entity 'Denmark' named entity '5-year survival' named entity 'randomized trial' named entity 'oncology' named entity 'radiotherapy' named entity 'disease-specific' named entity 'adverse effects' named entity 'resectable' named entity 'OSCC' named entity 'OSCC' named entity 'COVID-19' named entity 'Australia' named entity 'wound healing' named entity 'randomized controlled trials' named entity 'Chemoradiotherapy' named entity 'neoadjuvant' named entity 'immunomodulation' named entity 'oral cavity' named entity 'toxicity' named entity 'outpatient' named entity 'OSCC' named entity 'immune detection' named entity 'chemotherapy' named entity 'Meta-analysis' named entity 'SCC' named entity 'COVID-19' named entity 'confidence interval' named entity 'observational studies' named entity 'tumors' named entity 'kill cancer cells' named entity 'statistically significant' named entity 'randomized trials' named entity 'surgical treatment' named entity 'nosocomial' named entity 'immunotherapy' named entity 'Radiotherapy' named entity 'complete response' named entity 'COVID-19' named entity 'immunotherapies' named entity 'oral cavity' named entity 'post-operative' named entity 'induction chemotherapy' named entity 'radiotherapy' named entity 'COVID-19' named entity 'neoadjuvant' named entity 'oral cavity' named entity 'neoadjuvant' named entity 'induction therapy' named entity 'head and neck cancer' named entity 'tumor size' named entity 'oncological'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software